Quantib ND is software for the labeled brain MRI image-analysis workflow, providing release-specific visualization, measurements, or decision-support outputs for professional review.
Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.
Clinical fit
What this tool is for
Start with the authorized purpose, then verify how it fits your service line and reading workflow.
Exact purpose
Quantib ND is software for the labeled brain MRI image-analysis workflow, providing release-specific visualization, measurements, or decision-support outputs for professional review.
FDA source Exact FDA submission Checked 2026-09-04
Input protocol, anatomy, population, image quality, version, output-review, and local workflow limits require exact-release confirmation. Quantib ND is software for the labeled brain MRI image-analysis workflow, providing release-specific visualization, measurements, or decision-support outputs for professional review.
FDA source Exact FDA submission Checked 2026-09-04
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
FDA submission
K182564
FDA source Exact FDA submission Checked 2026-08-31
Use these fields to structure a vendor demo, security review, and implementation estimate.
Integration
Standards-based DICOM/PACS integration was identified in the FDA submission materials; compatibility with a specific PACS, RIS, EHR, or orchestrator requires confirmation.
Public source Exact FDA submission Checked 2026-08-13
Normalized from the prior exact-submission review. Confirm interface versions and local compatibility during technical evaluation.
Public source Exact FDA submission Checked 2026-08-13
Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.
Reviewed sources checked Exact FDA submission Checked 2026-09-04
Public sources reviewed here do not establish the complete exact-release security posture, including identity, audit, encryption, retention, remote access, vulnerability management, backup, or incident response.
Training and support
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-08-13
Training, onboarding, competency, and support commitments are commercial implementation details that require current vendor documentation.
Monitoring and change control
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-08-13
Local acceptance testing, production monitoring, drift review, update control, and incident escalation require a current vendor and site-specific governance plan.
Workflow role
Medical image analysis, visualization, measurement, triage, or reporting support as specified by the exact submission.
exact submission · checked 2026-09-04
This is a submission-anchored intended-use summary, not a local acceptance result.
Current vendor material is product-family context for K182564 only; exact release, enabled options, deployment, and local interoperability require confirmation.
product family · checked 2026-09-04
Vendor material is not exact-release evidence unless that linkage is separately proven.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.
Evidence summary
The exact FDA submission K182564 is the identity anchor. Its public decision material supports the submission-specific product and intended-use summary recorded here; it does not establish a general product-wide sensitivity or specificity value for this dossier.
FDA source Exact FDA submission Checked 2026-09-04
Reviewed sources checked Exact FDA submission Checked 2026-09-04
No exact submission and version-linked sensitivity endpoint is published in this dossier; do not substitute a product-family or candidate-study value.
Reported specificity
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04
No exact submission and version-linked specificity endpoint is published in this dossier; do not substitute a product-family or candidate-study value.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
FDA submission-specific verification and validation evidence for K182564
Regulatory verification, validation, and labeling evidence reviewed for exact FDA submission K182564. · The labeled population and test materials for exact submission K182564; a general clinical study population is not established here.
exact submission · Tested version: Quantib ND (K182564) · Sponsor or vendor study
K182564
FDA regulatory evidence is submission-specific but is not independent clinical performance evidence.
MRI approach to the patient with suspected dementia: artificial intelligence techniques and semi-quantitative rating scales compared.
Candidate peer-reviewed literature record discovered by exact-name or identifier search. · Candidate record population; product and version linkage to K182564 was not established.
product family · Tested version: Candidate product-family record; exact FDA submission and product version linkage not established. · Independence not established
41675581
Quarantined candidate evidence: do not treat this record as exact-submission performance evidence without product and version linkage review.
Longitudinal Brain Atrophy Rates in Presymptomatic Carriers of Genetic Frontotemporal Dementia.
Candidate peer-reviewed literature record discovered by exact-name or identifier search. · Candidate record population; product and version linkage to K182564 was not established.
product family · Tested version: Candidate product-family record; exact FDA submission and product version linkage not established. · Independence not established
36288997
Quarantined candidate evidence: do not treat this record as exact-submission performance evidence without product and version linkage review.
Combining semi-quantitative rating and automated brain volumetry in MRI evaluation of patients with probable behavioural variant of fronto-temporal dementia: an added value for clinical practise?
Candidate peer-reviewed literature record discovered by exact-name or identifier search. · Candidate record population; product and version linkage to K182564 was not established.
product family · Tested version: Candidate product-family record; exact FDA submission and product version linkage not established. · Independence not established
36867204
Quarantined candidate evidence: do not treat this record as exact-submission performance evidence without product and version linkage review.
These are common procurement questions; unknown values remain visible until a source supports them.
Pricing and total cost
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04
No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.
Reimbursement and coding
Not applicable
Not applicable Not applicable Checked 2026-09-04
CMS index context was checked, but no product-specific coverage or reimbursement determination is inferred.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Buyer worksheet
Open questions to take to the vendor
Verify security and privacy controls: Public sources reviewed here do not establish the complete exact-release security posture, including identity, audit, encryption, retention, remote access, vulnerability management, backup, or incident response.
Verify training: Training, onboarding, competency, and support commitments are commercial implementation details that require current vendor documentation.
Verify pricing and total cost: No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.
Verify reimbursement and coding relevance: CMS index context was checked, but no product-specific coverage or reimbursement determination is inferred.
Verify local validation and lifecycle monitoring: Local acceptance testing, production monitoring, drift review, update control, and incident escalation require a current vendor and site-specific governance plan.
Verify recalls and postmarket safety signals: No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-04Last searched
27Fields reviewed
12Source classes checked
3Unreviewed PubMed leads
0Unreviewed trial leads
0Unreviewed FDA recall leads
Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA identity, indication, modality, anatomy, workflow, and limitations were reviewed using the submission as the identity anchor. Current vendor material is product-family context only. PubMed and ClinicalTrials.gov candidates remain quarantined as product-family evidence because exact submission and version linkage was not established. CMS and openFDA index context was checked. Pricing, security, deployment, reimbursement, contracted services, enabled options, and local interoperability remain unknown unless separately evidenced. Automated exact-name discovery found 3 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads remain unpublished until a human confirms the exact product and tested version.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, pubmed, clinical trials, openfda device recall
ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained...
Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it...
Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.